Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Traws Pharma (TRAW) Revenue (2016 - 2025)

Traws Pharma (TRAW) has disclosed Revenue for 14 consecutive years, with $2.7 million as the latest value for Q2 2025.

  • For Q2 2025, Revenue rose 4694.74% year-over-year to $2.7 million; the TTM value through Dec 2025 reached $2.8 million, up 1134.51%, while the annual FY2025 figure was $2.8 million, 1134.51% up from the prior year.
  • Revenue hit $2.7 million in Q2 2025 for Traws Pharma, up from $57000.0 in the prior quarter.
  • Across five years, Revenue topped out at $2.7 million in Q2 2025 and bottomed at $56000.0 in Q1 2021.
  • Average Revenue over 5 years is $205222.2, with a median of $57000.0 recorded in 2021.
  • Year-over-year, Revenue fell 13.64% in 2021 and then skyrocketed 4694.74% in 2025.
  • Traws Pharma's Revenue stood at $56000.0 in 2021, then changed by 0.0% to $56000.0 in 2022, then changed by 0.0% to $56000.0 in 2023, then changed by 0.0% to $56000.0 in 2024, then surged by 4780.36% to $2.7 million in 2025.
  • According to Business Quant data, Revenue over the past three periods came in at $2.7 million, $57000.0, and $56000.0 for Q2 2025, Q1 2025, and Q4 2024 respectively.